BioCentury
ARTICLE | Clinical News

EC approves BMS's Sprycel for pediatric ALL

February 15, 2019 7:43 PM UTC

The European Commission approved Sprycel dasatinib from Bristol-Myers Squibb Co. (NYSE:BMY) in combination with chemotherapy to treat pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval covers both tablet and powder for oral suspension formulations of Sprycel.

FDA expanded Sprycel's label last month to include pediatric Ph+ ALL patients...

BCIQ Company Profiles

Bristol Myers Squibb Co.